Rosalba Mansi

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Neuroendocrine Tumors

Computed Tomography

Top Venues

Pharmaceuticals (Basel, Switzerland)

Journal of peptide science : an official publication of the European Peptide Society

Journal of labelled compounds & radiopharmaceuticals

This page only lists publications with an associated author ORCID identifier.

Publications

Luigi Aloj, Rosalba Mansi, Stefania De Luca, Antonella Accardo, Diego Tesauro, Giancarlo Morelli
Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy. Journal of peptide science : an official publication of the European Peptide Society (2024)
Berthold A Nock, Panagiotis Kanellopoulos, Lieke Joosten, Rosalba Mansi, Theodosia Maina
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists. Pharmaceuticals (Basel, Switzerland) 16 (5) (2023)
Melpomeni Fani, Rosalba Mansi, Guillaume P Nicolas, Damian Wild
Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals. Cancers 14 (5) (2022)
Pascale Plas, Lorenzo Limana, Denis Carré, Amath Thiongane, Olivier Raguin, Rosalba Mansi, Florence Meyer-Losic, Stéphane Lezmi
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [ 177 Lu]Lu-Satoreotide Tetraxetan and the Agonist [ 177 Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST 2 -Positive Tumours. Pharmaceuticals (Basel, Switzerland) 15 (9) (2022)
Rosalba Mansi, Berthold A Nock, Simone U Dalm, Martijn B Busstra, Thomas A Kirkland, Theodosia Maina
Radiolabeled Bombesin Analogs. Cancers 13 (22) (2021)
Raghuvir Haridas Gaonkar, Fabius Wiesmann, Luigi Del Pozzo, Lisa McDougall, Sandra Zanger, Renata Mikołajczak, Rosalba Mansi, Melpomeni Fani
SPECT Imaging of SST2-Expressing Tumors with 99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers. Pharmaceuticals (Basel, Switzerland) 14 (4) (2021)
Rosalba Mansi, Pascale Plas, Georges Vauquelin, Melpomeni Fani
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [ 177 Lu]Lu-OPS201 Compared to the Agonist [ 177 Lu]Lu-DOTA-TATE. Pharmaceuticals (Basel, Switzerland) 14 (12) (2021)
Melpomeni Fani, Viktoria Weingaertner, Petra Kolenc, Rosalba Mansi, Raghuvir H Gaonkar, Piotr Garnuszek, Renata Mikolajczak, Doroteja Novak, Urban Simoncic, Alicja Hubalewska-Dydejczyk, Christine Rangger, Piriya Kaeopookum, Clemens Decristoforo
Selection of the First 99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates. Pharmaceuticals (Basel, Switzerland) 14 (1) (2020)
Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, Karim Alexandre Abid, Eric Grouzmann, Melpomeni Fani
Evaluation of a New 177Lu-Labeled Somatostatin Analog for the Treatment of Tumors Expressing Somatostatin Receptor Subtypes 2 and 5. Molecules (Basel, Switzerland) 25 (18) (2020)
Rosalba Mansi, Melpomeni Fani
Design and development of the theranostic pair 177 Lu-OPS201/68 Ga-OPS202 for targeting somatostatin receptor expressing tumors. Journal of labelled compounds & radiopharmaceuticals 62 (10) (2019)